Skip to main content
Clinical Trials/NCT02961413
NCT02961413
Recruiting
Not Applicable

A Multi-center, Prospective, Non-interventional Cohort Study on Drug Induced Liver Injury in Mainland China

Drug Induced Liver Disease Study Group1 site in 1 country10,000 target enrollmentApril 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Drug-induced Liver Injury
Sponsor
Drug Induced Liver Disease Study Group
Enrollment
10000
Locations
1
Primary Endpoint
Disease progression of DILI (drug-induced liver injury ), i.e. death, liver failure, chronic DILI, recover
Status
Recruiting
Last Updated
12 months ago

Overview

Brief Summary

This is a multi-center, prospective, non-interventional cohort study .

Its primary objectives are:

  1. assess DILI patients' clinical characteristics, disease progression and influencing factors in clinical practice;
  2. learn about suspected drug caused DILI,rechallenging, liver biochemical abnormalities mode, etc.

Detailed Description

The main purpose of this study is to understand patients with DILI clinical outcome and influencing factors in China's second and tertiary general hospitals (including Western medicine hospital, Chinese medicine hospital andIntegrated traditional Chinese and Western Medicine Hospital) and vulnerabilities of drug-induced liver injury specialist hospital (tuberculosis hospital, Pulmonary, etc.) in mainland. The main purpose 1. assess the DILI patients' clinical outcomes and influencing factors in the real world; 2. learn about suspected drug caused DILI,rechallenging, liver biochemical abnormalities mode, etc. Secondary objectives 1. assess the compliance of the DILI practice to the 2015 vision of the DILI guidelines in china.; 2. evaluate the histological features of DILI patients; 3. assessment DILI characteristics, prognosis and influencing factors in specific populations(such as the elderly, children with underlying liver disease background, etc.)

Registry
clinicaltrials.gov
Start Date
April 2016
End Date
December 2030
Last Updated
12 months ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Drug Induced Liver Disease Study Group
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of DILI patients with various types and severity according to the 2015 version of the Chinese DILI treatment guidelines
  • RUCAM ≥6, or RUCAM between 3-5 is required by the three experts determined that the drug-induced liver injury
  • patient can provide informed consent form

Exclusion Criteria

  • non-drug-induced liver injury

Outcomes

Primary Outcomes

Disease progression of DILI (drug-induced liver injury ), i.e. death, liver failure, chronic DILI, recover

Time Frame: 6 months

Study Sites (1)

Loading locations...

Similar Trials